Surrozen to Present at Upcoming Healthcare Investor Conferences
10-Q: Q3 2024 Earnings Report
Surrozen: 3Q Collaboration and License Rev $10M >SRZN
Surrozen Q3 EPS $(0.44) Beats $(2.46) Estimate
Surrozen 3Q Loss/Shr 44c >SRZN
Express News | Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Press Release: Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Express News | Surrozen Inc - Tcgfb to Pay Surrozen up to $6 Million and Issue Warrants
Express News | Surrozen Inc - to Provide Antibody Discovery Services for up to Two Years
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
Express News | Surrozen and Tcgfb, Inc. Announce Strategic Research Collaboration to Develop Tgf-Β Antibodies for Idiopathic Pulmonary Fibrosis
Express News | Stempoint Capital LP Reports 12.8% Passive Stake in Surrozen Inc as of Oct 31 - SEC Filing
Express News | Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
Surrozen GAAP EPS of -$7.99
Surrozen Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Adjusted EPS Results.
Surrozen Q2 2024 Adj EPS $(7.99) Misses $(2.79) Estimate
10-Q: Q2 2024 Earnings Report
Surrozen: Cash and Cash Equivalents Were $37.8M as of June 30, Compared to $27.3M as of March 31 >SRZN
Surrozen 2Q Loss/Shr $7.99 >SRZN
No Data
No Data